[go: up one dir, main page]

UY25795A1 - Procedimiento para preparar pirazolopirimidinonas que inhiben la guanosina 3',5'- monofosfato cíclico fodfodiesterasa 5 (gmpc pde5). - Google Patents

Procedimiento para preparar pirazolopirimidinonas que inhiben la guanosina 3',5'- monofosfato cíclico fodfodiesterasa 5 (gmpc pde5).

Info

Publication number
UY25795A1
UY25795A1 UY25795A UY25795A UY25795A1 UY 25795 A1 UY25795 A1 UY 25795A1 UY 25795 A UY25795 A UY 25795A UY 25795 A UY25795 A UY 25795A UY 25795 A1 UY25795 A1 UY 25795A1
Authority
UY
Uruguay
Prior art keywords
prepare
procedure
guanosine
heterocycle
alkyl
Prior art date
Application number
UY25795A
Other languages
English (en)
Inventor
Mathias John Paul
Rawson David James
Maw Graham Nigel
Wood Anthony
Stephen D A Street
Bunnage Mark Edward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY25795A1 publication Critical patent/UY25795A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Procedimiento para preparar compuestos de pirazolopirimidinonas de fórmula IA y de fórmula IB, en las que: A representa CH o N; R1 representa H, alquilo, heterociclo, arilo o alquilarilo; R2 representa C(O)NR12R13, C(O)OR12, NR12R13, N(H)SO2R12, N(H)SO2NR12R13, N(H)C(O)R12, alquilo, ciano, arilo o heterociclo; R3, R12 y R13 representan independientemente H o alquilo; R4 representa SO2NR14R15; R14 y R15, junto con el nitrógeno al que están unidos, forman un heterociclo; y a sales farmacéuticamente aceptables de los mismos. Dichos compuestos son útiles en el tratamiento curativo y profiláctico de afecciones médicas para las que se desea la inhibición de una guanosina 3',5'- monofosfato cíclico fosfodiesterasa (por ejemplo, GMPc PDE5), tales como la disfunción eréctil en machos (MED). Ej. no limitante: 5-[5-(4-metilpiperazin-1-ilsulfonil)-2-n-propoxifenil]-7-oxo-1-(piridin-2-il)metil-1,6-dihidro-1H-pirazol[4,3-d]pirimidina-3-carboxamida
UY25795A 1998-10-23 1999-11-11 Procedimiento para preparar pirazolopirimidinonas que inhiben la guanosina 3',5'- monofosfato cíclico fodfodiesterasa 5 (gmpc pde5). UY25795A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9823102.0A GB9823102D0 (en) 1998-10-23 1998-10-23 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
UY25795A1 true UY25795A1 (es) 2000-08-21

Family

ID=10841068

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25795A UY25795A1 (es) 1998-10-23 1999-11-11 Procedimiento para preparar pirazolopirimidinonas que inhiben la guanosina 3',5'- monofosfato cíclico fodfodiesterasa 5 (gmpc pde5).

Country Status (7)

Country Link
US (1) US6333330B1 (es)
GB (1) GB9823102D0 (es)
GT (1) GT199900183A (es)
MA (1) MA26701A1 (es)
PE (1) PE20001114A1 (es)
TN (1) TNSN99198A1 (es)
UY (1) UY25795A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
US7405222B2 (en) 2002-01-25 2008-07-29 Modular Properties, Ltd. Methods and compositions for treatment of erectile dysfunction
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
EP1847531A4 (en) * 2005-02-09 2009-04-22 Takeda Pharmaceutical PYRAZOLE DERIVATIVE
CA2647932C (en) * 2006-04-04 2011-06-07 Dong A Pharm. Co. Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371843A (en) 1980-07-07 1983-02-01 Bell Telephone Laboratories, Incorporated Semiconductor differential amplifier circuit with feedback bias control
US4670978A (en) 1985-01-28 1987-06-09 Amp Incorporated Connector mounting press
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CA2211729A1 (en) 1995-03-10 1996-09-19 Sanofi Pharmaceuticals, Inc. 6-aryl pyrazolo[3,4-d¦pyrimidin-4-ones and compositions and methods of use thereof
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
ID22834A (id) 1997-04-25 1999-12-09 Pfizer Pirazolopimidinona untuk kelainan seksual
PT1073658E (pt) 1998-04-20 2003-12-31 Pfizer Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds

Also Published As

Publication number Publication date
US6333330B1 (en) 2001-12-25
PE20001114A1 (es) 2000-10-28
GT199900183A (es) 2001-04-14
TNSN99198A1 (fr) 2005-11-10
MA26701A1 (fr) 2004-12-20
GB9823102D0 (en) 1998-12-16

Similar Documents

Publication Publication Date Title
UY25795A1 (es) Procedimiento para preparar pirazolopirimidinonas que inhiben la guanosina 3',5'- monofosfato cíclico fodfodiesterasa 5 (gmpc pde5).
PE20010736A1 (es) PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA
UY25484A1 (es) Procedimiento para preparar pirazolopirimidinonas que inhiben la guanosina 3',5'-monofosfato cíclica fosfodiesterasa de tipo 5
BR0014698A (pt) Derivados de pirazolo [4,3-d] pirimidina
BR9810233A (pt) Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
RU2394826C2 (ru) Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы
DE60002969D1 (de) Imidazo[5,1-f][1,2,4]triazinderivate
RU2412171C2 (ru) Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы
DE60204760D1 (de) Pyrazolo[4,3-d]pyrimidinon-verbindungen als cgmp pde-inhibitoren
WO2002064590A3 (en) Carboline derivatives
CA2287552A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
DE69925970D1 (de) Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
CA2347950A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
WO2002064591A3 (en) Carboline derivatives
JPWO2020150474A5 (es)
JP2022534501A (ja) 三環式化合物
AR035650A1 (es) Procedimiento para la preparacion de compuestos de pirazolo[4,3-d]pirimidin-7-ona
WO2002079203A8 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AR044648A1 (es) Combinaciones terapeuticas
ATE397606T1 (de) Pyrazino(1',2':1,6)-pyrido(3,4-b) indole-1,4- dionderivate
JP2004528320A5 (es)
AP2002002462A0 (en) Pharmaceutically active compounds.
ES2244659T3 (es) Derivados de hexahidropirazino (1'2':1,6)-pirido(3,4-b)indol-1,4-diona para el tratamiento de trastornos cardiovasculares y disfuncion erectil.
AR033387A1 (es) Derivados de pirrolotriazolopirimidinona; procedimiento para preparar dichos derivados; compuestos intermediarios utilizables en dicho procedimiento; composiciones farmaceuticas formuladas con los derivados mencionados; uso de los derivados mencionados en la manufactura de medicamentos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110627